期刊
LIVER INTERNATIONAL
卷 31, 期 -, 页码 29-35出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1478-3231.2010.02389.x
关键词
Genetics; HCV; IL28B; treatment response
资金
- Schering Plough
- Merck
It has been understood for some time that the treatment outcome of hepatitis C virus (HCV) infection is influenced by host genetic factors. Three independent genome-wide association studies have recently identified that a genetic variation in the IL28B gene [interferon-lambda 3 (IFN-lambda 3)] determines the outcome of IFN-alpha-based therapy in patients with genotype 1 chronic hepatitis C infection. This genetic polymorphism is also strongly associated with a higher likelihood of spontaneous clearance following acute hepatitis C infection. These results confirm the importance of specific host genetic markers in predicting outcome and treatment response. They also provide the framework and potential for a clinically relevant and meaningful pharmacogenomic approach to personalizing anti-HCV treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据